Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Despite improvements in pharmacotherapy, morbidity and mortality rates in community-
based populations with chronic heart failure still remain high. The increase in medical …

Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk
of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with …

While there is consensus on starting urate-lowering therapy (ULT) in cases of symptomatic
hyperuricemia, the frequent condition of asymptomatic hyperuricemia (AH) remains a …

Objectives: Explain the pathophysiology of hyperuricemia. Describe typical history and
physical exam findings in a patient with hyperuricemia. Identify treatment modalities for both …

Uric acid (UA) is the end product of purine metabolism, and its concentration in blood can
increase in humans, great apes, and dalmatian dogs as a consequence of a genetic …

The interest in uric acid and its clinical implications dates back to ancient times. Gouty
arthritis was first identified in 2640 BC by the Egyptians, followed by Hippocrates (460–377 …

Affecting more than 26 million people worldwide and with rising prevalence, heart failure
(HF) represents a major global health problem. Hence, further research is needed in order to …

The aim of the work is a literature review of published clinical studies on the effects of
hyperuricemia on the course of chronic heart failure (CHF). Results. High levels of uric acid …

The role of uric acid levels in the cardiovascular continuum is not clear. Our objective is to
analyze the prevalence of hyperuricemia (HU) and its association with cardiovascular risk …